

2025 Highlights

IMPACTING PATIENTS WORLDWIDE

Over 400,000

patients treated with medicines commercialized by Incyte

~280,000

patients assisted through U.S. patient support and copay assistance programs

5+ global

regulatory approvals across multiple products, and advanced numerous assets from early- to late-stage development

DRIVING INNOVATION AND GROWTH

10 approved

products* and ongoing clinical trials in multiple disease areas

~950

research and development employees

2,800+

employees in North America, Europe and Asia

GIVING BACK AND STRENGTHENING COMMUNITIES

43%

of our global employees used their paid volunteer day

650+

organizations received matched gifts through our Matching Gifts Program

\$1M+ donated

through the Incyte Charitable Giving Foundation

A RECOGNIZED LEADER

8 consecutive

years named a top 3 industry employer by *Science Magazine*

Ranked #35

on *Newsweek's* Global Most Loved Workplaces list

COMMITMENT TO GLOBAL RESPONSIBILITY

Our 2025 cash incentive bonus program linked to

2 measurable ESG goals

REINFORCING A CULTURE OF ETHICS AND COMPLIANCE

Maintained strong ethics and compliance standards, providing training on ethics, cybersecurity and more.

Our 2025 global employee engagement survey reflected strong employee confidence in Incyte's commitment to address ethics and integrity concerns.

*This number includes partnered programs.